JMI LABS IS NOW PART OF LEARN MORE

Filter by Category: Antimicrobial Surveillance

WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against gram-negative organisms producing clinically relevant beta-lactamases.

WCK 5222 (cefepime/zidebactam) antimicrobial activity tested against gram-negative organisms producing clinically relevant beta-lactamases. by Sader HS, Rhomberg PR, Flamm RK, Jones RN and Castanheira M published in J. Antimicrob. Chemother. 2017; 72 (6): 1696-1703

Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012-2015) of the International Network for Optimal Resistance Monitoring program in the United States.

Pseudomonas aeruginosa antimicrobial susceptibility results from four years (2012-2015) of the International Network for Optimal Resistance Monitoring program in the United States. by Sader HS, Huband MD, Castanheira M and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (3): e02252

Antimicrobial activity of high-proportion cefepime-tazobactam (WCK 4282) against a large number of gram-negative isolates collected worldwide in (2014).

Antimicrobial activity of high-proportion cefepime-tazobactam (WCK 4282) against a large number of gram-negative isolates collected worldwide in (2014). by Sader HS, Castanheira M, Mendes RE, Flamm RK and Jones RN published in Antimicrob. Agents. Chemother. 2017; 61 (4): e02409

Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014).

Antimicrobial activity of ceftazidime-avibactam and comparator agents when tested against bacterial isolates causing infection in cancer patients (2013-2014). by Sader HS, Castanheira M, Jones RN and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2017; 87 (3): 261-265

WCK 5222 (cefepime-zidebactam) antimicrobial activity tested against clinical isolates of gram-negative bacteria collected worldwide (2015).

WCK 5222 (cefepime-zidebactam) antimicrobial activity tested against clinical isolates of gram-negative bacteria collected worldwide (2015). by Sader HS, Castanheira M, Huband M, Jones RN and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (5): 00072

Antimicrobial activity of ceftazidime-avibactam against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2011-2015).

Antimicrobial activity of ceftazidime-avibactam against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2011-2015). by Sader HS, Castanheira M and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (4): e02083

Activities of omadacycline and comparator agents when tested against Staphylococcus aureus from a surveillance program conducted in North America and Europe.

Activities of omadacycline and comparator agents when tested against Staphylococcus aureus from a surveillance program conducted in North America and Europe. by Pfaller MA, Rhomberg PR, Huband MD and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (3): e02411

Ceftaroline activity against multidrug-resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and molecular characterization of a single ceftaroline nonsusceptible isolate.

Ceftaroline activity against multidrug-resistant Streptococcus pneumoniae from U.S. Medical Centers (2014) and molecular characterization of a single ceftaroline nonsusceptible isolate. by Pfaller MA, Mendes RE, Flamm RK, Jones RN and Sader HS published in Microb. Drug Resist. 2017; 23 (5): 571-579

Surveillance of omadacycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Western Pacific) collection (2010-2011).

Surveillance of omadacycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Western Pacific) collection (2010-2011). by Pfaller MA, Huband MD, Rhomberg PR and Flamm RK published in Antimicrob. Agents Chemother. 2017; 61 (5): e00018-00017

Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014).

Antimicrobial activity of tigecycline and cefoperazone/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013-2014). by Pfaller MA, Flamm RK, Duncan LR, Mendes RE, Jones RN and Sader HS published in Diagn. Microbiol. Infect. Dis. 2017; 88 (2): 177-183

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: Report from an antimicrobial surveillance programme (2012-15).

Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: Report from an antimicrobial surveillance programme (2012-15). by Pfaller MA, Bassetti M, Duncan LR and Castanheira M published in J. Antimicrob. Chemother. 2017; 72 (5): 1386-1395

Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014).

Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011-2014). by Mendes RE, Sader HS, Smart JI, Castanheira M and Flamm RK published in Eur. J. Clin. Microbiol. Infect. Dis. 2017; 36 (6): 1013-1017

Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations.

Activity of telavancin against Gram-positive pathogens isolated from bone and joint infections in North American, Latin American, European and Asia-Pacific nations. by Jones RN, Flamm RK, Castanheira M, Sader HS, Smart JI and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2017; 88 (2): 184-187

Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012-2014).

Antimicrobial susceptibility patterns of community- and hospital-acquired methicillin-resistant Staphylococcus aureus from United States Hospitals: results from the AWARE Ceftaroline Surveillance Program (2012-2014). by Sader HS, Mendes RE, Jones RN and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2016; 86 (1): 76-79

Antimicrobial activities of ceftazidime-avibactam and comparator agents against Gram-negative organisms isolated from patients with urinary tract infections in U.S. Medical Centers, 2012 to 2014.

Antimicrobial activities of ceftazidime-avibactam and comparator agents against Gram-negative organisms isolated from patients with urinary tract infections in U.S. Medical Centers, 2012 to 2014. by Sader HS, Castanheira M, Flamm RK and Jones RN published in Antimicrob. Agents. Chemother. 2016; 60 (7): 4355-4360

Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): Evolving resistance mechanisms with stable susceptibility rates.

Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): Evolving resistance mechanisms with stable susceptibility rates. by Mendes RE, Hogan PA, Jones RN, Sader HS and Flamm RK published in J. Antimicrob. Chemother. 2016; 71 (7): 1860-1865

Omadacycline Activity Tested Against European Bacterial Isolates from a Combined 2010-2011 Global Surveillance Program

Omadacycline Activity Tested Against European Bacterial Isolates from a Combined 2010-2011 Global Surveillance Program, Lead author: Flamm RK, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

The Activity of Tedizolid against Gram-positive Pathogens Isolated from Patients in Medical Centres in Europe, Turkey and Israel: 2014 Surveillance

The Activity of Tedizolid against Gram-positive Pathogens Isolated from Patients in Medical Centres in Europe, Turkey and Israel: 2014 Surveillance, Lead author: Farrell DJ, presented at 26th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 9-12, 2016, Amsterdam, Netherlands

Results from the Solithromycin International Surveillance Program (2014).

Results from the Solithromycin International Surveillance Program (2014). by Farrell DJ, Flamm RK, Sader HS and Jones RN. published in Antimicrob. Agents. Chemother. 2016; 60 (6): 3662-3668, 2016

Ceftaroline activity tested against viridans group streptococci from US hospitals.

Ceftaroline activity tested against viridans group streptococci from US hospitals. by Sader HS, Rhomberg PR, Castanheira M, Farrell DJ, Flamm RK, Mendes RE and Jones RN. published in Diagn. Microbiol. Infect. Dis. 2016; 84 (3): 232-235

Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13).

Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13). by Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS and Jones RN. published in J. Antimicrob. Chemother. 2016; 71 (1): 276-278

Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative Staphylococcus causing infection in US hospitals.

Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative Staphylococcus causing infection in US hospitals. by Sader HS, Farrell DJ, Flamm RK, Streit JM, Mendes RE and Jones RN. published in Diagn. Microbiol. Infect. Dis. 2016; 85 (1): 80-84

Antimicrobial activity of ceftaroline tested against Staphylococcus aureus from surgical skin and skin structure infections in US Medical Centers.

Antimicrobial activity of ceftaroline tested against Staphylococcus aureus from surgical skin and skin structure infections in US Medical Centers. by Sader HS, Farrell DJ, Flamm RK and Jones RN. published in Surg. Infect. (Larchmt) 2016; 17 (4): 443-447

Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): Evolving resistance mechanisms with stable susceptibility rates.

Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): Evolving resistance mechanisms with stable susceptibility rates. by Mendes RE, Hogan PA, Jones RN, Sader HS and Flamm RK published in J. Antimicrob. Chemother. 2016; 71 (7):1860-1865

Results from oritavancin resistance surveillance programs (2011-2014): Clarification for using vancomycin as a surrogate to infer oritavancin susceptibility.

Results from oritavancin resistance surveillance programs (2011-2014): Clarification for using vancomycin as a surrogate to infer oritavancin susceptibility. by Jones RN, Moeck G, Arhin FF, Dudley MN, Rhomberg PR and Mendes RE published in Antimicrob. Agents. Chemother. 2016; 60 (5): 3174-3177

Linezolid surveillance results for the United States (LEADER Surveillance Program 2014).

Linezolid surveillance results for the United States (LEADER Surveillance Program 2014). by Flamm RK, Mendes RE, Hogan PA, Streit JM, Ross JE and Jones RN. published in Antimicrob. Agents Chemother. 2016; 60 (4): 2273-2280

The Actvity of Tedizolid against Gram-positive Pathogens from USA Medical Centers: 2014 Surveillance

The Actvity of Tedizolid against Gram-positive Pathogens from USA Medical Centers: 2014 Surveillance, Lead author: Farrell DJ, presented at ID Week, October 7-11, 2015, San Diego, CA

In Vitro Activity of Minocycline Against A. baumannii, S. maltophilia and B. cepacia Isolated in 2013 from a Global Surveillance Program

In Vitro Activity of Minocycline Against A. baumannii, S. maltophilia and B. cepacia Isolated in 2013 from a Global Surveillance Program, Lead author: Flamm RK, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Activity of Omadacycline Tested against Streptococcus pneumoniae from a Global Surveillance Porgram (2014)

Activity of Omadacycline Tested against Streptococcus pneumoniae from a Global Surveillance Porgram (2014), Lead author: Flamm RK, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Activity of Omadacycline Tested against Enterobacteriaceae Causing Urinary Tract Infections from a Global Surveillance Porgram (2014)

Activity of Omadacycline Tested against Enterobacteriaceae Causing Urinary Tract Infections from a Global Surveillance Porgram (2014), Lead author: Flamm RK, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Activity of Solithromycin Against Pathogens Associated with CABP: Global Surveillance Results from 2014

Activity of Solithromycin Against Pathogens Associated with CABP: Global Surveillance Results from 2014, Lead author: Farrell DJ, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Activity of Omadacycline Tested Against S. aureus from a Global Surveillance Program (2014)

Activity of Omadacycline Tested Against S. aureus from a Global Surveillance Program (2014), Lead author: Flamm RK, presented at 55th annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), September 17-21,2015, San Diego, CA

Minocycline activity tested against A. baumannii, B. cepacia, S. maltophila, and select Enterobacteriaceae isolates from a European surveillance program (2013)

Minocycline activity tested against A. baumannii, B. cepacia, S. maltophila, and select Enterobacteriaceae isolates from a European surveillance program (2013), Lead author: Flamm RK, presented at 25th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 25-29, 2015, Copenhagen, Denmark

Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013.

Antimicrobial activity of ceftaroline tested against bacterial isolates causing respiratory tract and skin and skin structure infections in US medical centers in 2013. by Sader HS, Farrell DJ, Mendes RE, Flamm RK, Castanheira M and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 82 (1): 78-84

Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012.

Antimicrobial activity of solithromycin against serotyped macrolide-resistant Streptococcus pneumoniae isolates collected from U.S. medical centers in 2012. by Farrell DJ, Mendes RE and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (4): 2432-2434

Telavancin in vitro activity against a USA collection of methicillin-resistant Staphylococcus aureus, including resistant subsets.

Telavancin in vitro activity against a USA collection of methicillin-resistant Staphylococcus aureus, including resistant subsets. by Mendes RE, Sader HS, Flamm RK, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (3): 1811-1814

Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014).

Ceftazidime-avibactam activity when tested against ceftazidime-nonsusceptible Citrobacter spp., Enterobacter spp., Serratia marcescens, and Pseudomonas aeruginosa from Unites States medical centers (2011-2014). by Sader HS, Castanheira M, Farrell DJ, Flamm RK and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 83 (4): 389-394

Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-2013).

Activity of oritavancin against Gram-positive clinical isolates responsible for documented skin and soft-tissue infections in European and US hospitals (2010-2013). by Mendes RE, Farrell DJ, Sader HS, Flamm RK and Jones RN published in J. Antimicrob. Chemother. 2015; 70 (2): 498-504

Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: Redefining the baseline activity of telavancin.

Telavancin activity tested against Gram-positive clinical isolates from European, Russian and Israeli hospitals (2011-2013) using a revised broth microdilution testing method: Redefining the baseline activity of telavancin. by Mendes RE, Flamm RK, Farrell DJ, Sader HS and Jones RN published in J. Chemother. 2016; 28 (2): 83-88

Detection of a new cfr-like gene, cfr(B), in Enterococcus faecium recovered from human specimens in the United States: Report from The SENTRY Antimicrobial Surveillance Program.

Detection of a new cfr-like gene, cfr(B), in Enterococcus faecium recovered from human specimens in the United States: Report from The SENTRY Antimicrobial Surveillance Program. by Deshpande LM, Ashcraft DS, Kahn HP, Pankey G, Jones RN, Farrell DJ and Mendes RE published in Antimicrob. Agents. Chemother. 2015; 59 (10): 6256-6261,

Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013).

Telavancin activity when tested by a revised susceptibility testing method against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013). by Mendes RE, Sader HS, Flamm RK, Farrell DJ and Jones RN published in J. Global Antimicrob. Res. 2015; 3 (1): 36-39

Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009–13).

Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009–13). by Sader HS, Farrell DJ, Flamm RK and Jones RN. published in J. Antmicrob. Chemother. 2015; 70 (7): 2053-2056,

Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia.

Ceftazidime/avibactam tested against Gram-negative bacteria from intensive care unit (ICU) and non-ICU patients, including those with ventilator-associated pneumonia. by Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ and Jones RN. published in Int. J. Antimicrob. Agents. 2015; 46 (1): 53-59

Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012).

Antifungal susceptibilities of Candida, Cryptococcus neoformans and Aspergillus fumigatus from the Asia and Western Pacific region: data from the SENTRY antifungal surveillance program (2010-2012). by Pfaller MA, Messer SA, Jones RN and Castanheira M. published in J. Antibiot. (Tokyo) 2015; 68 (9): 556-561

In vitro activity of dalbavancin against drug resistant Staphylococcus aureus from a global surveillance program.

In vitro activity of dalbavancin against drug resistant Staphylococcus aureus from a global surveillance program. by McCurdy SP, Jones RN, Mendes RE, Puttagunta S and Dunne MW published in Antimicrob. Agents Chemother. 2015; 59 (8): 5007-5009

Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program.

Ceftaroline activity against bacterial pathogens frequently isolated in U.S. medical centers: results from five years of the AWARE surveillance program. by Sader HS, Flamm RK, Streit J, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2015; 59 (4): 2458-2461,

Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009–13).

Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009–13). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in J. Antmicrob. Chemother. 2015; 70 (7): 2053-2056, 2015

In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program.

In vitro activity of linezolid as assessed through the 2013 LEADER surveillance program. by Flamm RK, Mendes RE, Hogan PA, Ross JE, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2015; 81 (4): 283-289

Ceftazidime-avibactam activity tested against Enterobacteriaceae from United States hospitals (2011-2013) and characterization of beta-lactamase producing strains.

Ceftazidime-avibactam activity tested against Enterobacteriaceae from United States hospitals (2011-2013) and characterization of beta-lactamase producing strains. by Castanheira M, Mills JC, Costello SE, Jones RN and Sader HS published in Antimicrob. Agents Chemother. 2015; 59 (6): 3509-3517

Ceftazidime-avibactam activity tested against multidrug-resistant Pseudomonas aeruginosa isolated from United States Medical Centers (2012-2013).

Ceftazidime-avibactam activity tested against multidrug-resistant Pseudomonas aeruginosa isolated from United States Medical Centers (2012-2013). by Sader HS, Castanheira M, Mendes RE, Flamm RK, Farrell DJ and Jones RN. published in Antimicrob. Agents Chemother.. 2015; 59 (6): 3656-3659